Field Trip completes FY2021 as the largest vertically integrated psychedelics company positioned to be a leader in the emerging industry Continues to leverage its early mover opportunity by investing in its drug development strategy and the build out of a globally recognized brand of psychedelic-assisted therapy centers Closed FY2021 with $111,817,443 in unrestricted cash and cash equivalents…


Previous articleWesana Health Partners with University of South Carolina
Next articleUK Set to Become Hub of Psychedelic Research, as British Startup Gears-up to Run Trials for International Psychedelic Drug Developers